Objective
Carotid artery disease, the primary trigger of ischaemic cerebrovascular events including stroke, causes major morbidity, mortality and healthcare costs worldwide. Still, treatment is based on criteria established in the 90s that do not take into account the molecular evolution we have witnessed since, nor the introduction of new medication, leading to remarkably high unnecessary surgical treatment while missing most patients at risk.
TAXINOMISIS will provide novel disease mechanism-based stratification for carotid artery disease patients to address the needs for stratified and personalised therapeutic interventions in the current era. This will be achieved through (1) the dissection of mechanisms mediating carotid artery disease, and identification of susceptibility and protection factors of plaque erosion and/or rupture using longitudinal cohorts and multi-omics, (2) the definition of distinct disease phenotypes and endotypes, and generation of molecular fingerprints of high versus low-risk states through systems medicine, (3) the development of a multilevel risk prediction model of the symptomatic plaque incorporating new biomarkers and advanced imaging, implemented in a software, to assist patient stratification and clinical decision making, (4) the development of novel pharmacogenomics solutions based on lab-on-a-chip technology to support personalized treatment, (5) the evaluation of the new risk prediction model and lab-on-a-chip device in a prospective observational clinical study, and (6) the assessment of regulatory, cost-effectiveness and ethical issues towards the implementation and commercialization of the programme’s outcomes.
TAXINOMISIS has therefore the potential to rationally change the current state-of-the-art in the stratification of patients with carotid artery disease by reducing unnecessary operations, refining medical treatment and opening up new avenues for therapeutic intervention, while strengthening the European biotechnology sector.
Fields of science
Not validated
Not validated
- social sciencessociologydemographymortality
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- engineering and technologyother engineering and technologiesmicrotechnologylab on a chip
- medical and health sciencesbasic medicineneurologystroke
- natural sciencesbiological sciencesmolecular biologymolecular evolution
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
45110 Ioannina
Greece
See on map
Participants (16)
3584 CX Utrecht
See on map
81675 Muenchen
See on map
11000 Belgrade
See on map
3001 Leuven
See on map
115 27 Athina
See on map
OX1 2JD Oxford
See on map
02150 Espoo
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
33520 Tampere
See on map
3500 BN Utrecht
See on map
16132 Genova
See on map
10561 Athina
See on map
08036 Barcelona
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
08036 Barcelona
See on map
34000 Kragujevac
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
00144 Roma
See on map
000 Zurich
See on map